

Increasing HIV In Women Is A Key Driver For The Cervical Cancer Drugs Market

*The Business Research Company's
Cervical Cancer Drugs Global Market
Report 2021 - COVID-19 Impact And
Recovery*

LONDON, GREATER LONDON, UK,
October 13, 2021 /EINPresswire.com/ --


The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of [the cervical cancer drugs market](#). Women that are HIV positive have a greater risk of cervical cancer than the general

population. Nearly 18 million women have tested HIV positive globally; HIV weakens the immune system, which increases the likelihood of cervical cancer. Women with HIV have an increased chance of being diagnosed with cervical cancer because the count of the protein CD4 goes down. According to a survey conducted by the National cancer institute, a person with HIV is three times as likely to be diagnosed with cervical cancer.

The cervical cancer drugs market is experiencing a number of significant trends that helps in efficient and targeted treatment of the disease including advances in drug delivery. One such trend is the use of drugs that can be delivered directly to the vagina such as drugs using vaginal formulations as gels, creams, pessaries, rings, films and tablets. These drugs ease the localized treatment of cervical cancer. The formulation of these drugs is in such a way that they get easily absorbed into vaginal tissue and reach the site of action. For instance, companies introduced vaginal gels such as Cidofovir gel and 851B Gel into the market to treat cervical cancer. As per the reports by International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)'s Clinical Trials Registry, 851B Gel is in trial phase. Whereas Cidofovir gel, sold under the brand name Vistide, is already a success in the market. In addition to the above-mentioned gels, drugs such as ISA101, AGEN2034 and Z-100 are in pipeline and promise growth to the cervical cancer drugs market.

Read More On The Global Cervical Cancer Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/cervical-cancer-drugs-global-market->



[report](#)

The global [cervical cancer drugs market size](#) is expected to grow from \$7.92 billion in 2020 to \$8.09 billion in 2021 at a compound annual growth rate (CAGR) of 2.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach \$9.73 billion in 2025 at a CAGR of 4.7%.

Major players covered in the global cervical cancer drugs industry are F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer.

TBRC's global cervical cancer drugs market report is segmented by cancer type into squamous cell cancer, adenocarcinoma, by drug type into avastin, bevacizumb, blemocin, blenoxane, others, by distribution channel into hospitals pharmacies, retail pharmacies, others.

Cervical Cancer Drugs Global Market Report 2021 - By Cancer Type (Squamous Cell Cancer, Adenocarcinoma), By Drug Type (Avastin, Bevacizumab, Bleomycin, Blenoxane), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies), COVID-19 Impact And Recovery one of a series of new reports from The Business Research Company that provides cervical cancer drugs market overview, forecast cervical cancer drugs market size and growth for the whole market, cervical cancer drugs market segments, and geographies, cervical cancer drugs market trends, cervical cancer drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Cervical Cancer Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2589&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Gastric Cancer Drugs Market - By Type (Imatinib, Trastuzumab), By End-User (Hospitals, Clinics Cancer Specialty Centers), By Route of Administration (Oral, Parental) And By Region, Opportunities And Strategies – Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market>

Colorectal Cancer Drugs Global Market Report 2021 - By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies), By Class (Immunotherapy, Chemotherapy), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report>

Kidney Cancer Drugs Global Market Report 2021 - By Type (Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirrolimus), Proleukin (Aldesleukin)), By End Users (Hospitals, Clinics, Research Center), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report>

Interested to know more about [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Or get a quick glimpse of our services here:

https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/553643857>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.